Clinical trial

Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study

NCT04575415

Study summary

ClinicalTrials.gov

Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study

Design: OBSERVATIONAL · Status: UNKNOWN · Phase: Not specified

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

7 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Bevacizumab Normalized identity: bevacizumab View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Erlotinib Normalized identity: erlotinib View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Gefitinib Normalized identity: gefitinib View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Icotinib Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Afatinib Normalized identity: afatinib View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Dacomitinib Normalized identity: dacomitinib View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Osimertinib Normalized identity: osimertinib View linked drug · Find medicine records · Find other trials using this name

StatusUNKNOWN

Study typeOBSERVATIONAL

Start date2020-10-07

PhaseN/A

Conditions

NSCLCverified · MONDO: non-small cell lung carcinoma

Interventions

BevacizumabDRUG · verified · RxNorm: bevacizumab

ErlotinibDRUG · verified · RxNorm: erlotinib

GefitinibDRUG · verified · RxNorm: gefitinib

IcotinibDRUG

AfatinibDRUG · verified · RxNorm: afatinib

DacomitinibDRUG · verified · RxNorm: dacomitinib

OsimertinibDRUG · verified · RxNorm: osimertinib

Sponsors & collaborators

Guangdong Association of Clinical Trialslead sponsor

Mapped research locations

GuangzhouGuangdong, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04575415 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.